New Releases

Premium

Ipsogen this week launched of a new line of assays that enable the standardization of quantitative analysis of BCR-ABL Mbcr by calibrating the results on the International Scale.

Ipsogen said that its BCR-ABL Mbcr IS-MMR DX and BCR-ABL Mbcr IS-MMR kits have CE-marking and are already available in Europe and other non-US markets. Research-use-only kits are planned for launch in North America next year.

Standardization of the analysis of BCR-ABL transcripts is increasingly viewed as medically necessary when administering drugs like Gleevec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.